Cargando…

The albumin-bilirubin score stratifies the outcomes of Child-Pugh class A patients after resection of hepatocellular carcinoma

BACKGROUND: The albumin-bilirubin (ALBI) score is a mathematical model including serum albumin and bilirubin, recently proposed as an alternative prognostic tool in patients with hepatocellular carcinoma (HCC). The aims of this study were to provide evidence that the ALBI score can identify differen...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruzzenente, Andrea, De Angelis, Michela, Conci, Simone, Campagnaro, Tommaso, Isa, Giulia, Bagante, Fabio, Ciangherotti, Andrea, Pedrazzani, Corrado, Capelli, Paola, Iacono, Calogero, Guglielmi, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798373/
https://www.ncbi.nlm.nih.gov/pubmed/35117104
http://dx.doi.org/10.21037/tcr.2018.12.10
_version_ 1784641789501636608
author Ruzzenente, Andrea
De Angelis, Michela
Conci, Simone
Campagnaro, Tommaso
Isa, Giulia
Bagante, Fabio
Ciangherotti, Andrea
Pedrazzani, Corrado
Capelli, Paola
Iacono, Calogero
Guglielmi, Alfredo
author_facet Ruzzenente, Andrea
De Angelis, Michela
Conci, Simone
Campagnaro, Tommaso
Isa, Giulia
Bagante, Fabio
Ciangherotti, Andrea
Pedrazzani, Corrado
Capelli, Paola
Iacono, Calogero
Guglielmi, Alfredo
author_sort Ruzzenente, Andrea
collection PubMed
description BACKGROUND: The albumin-bilirubin (ALBI) score is a mathematical model including serum albumin and bilirubin, recently proposed as an alternative prognostic tool in patients with hepatocellular carcinoma (HCC). The aims of this study were to provide evidence that the ALBI score can identify different prognostic groups in Child-Pugh (CP) class A patients undergoing liver resection with curative intent and to verify the ability of the ALBI score to predict short-term and long-term outcomes. METHODS: We performed a retrospective analysis on patients classified as class A according to the CP score who underwent liver resection with curative intent for HCC between 2006 and 2016 in the Division of Hepatobiliary Surgery at the University of Verona. Patients were divided according to the ALBI score and the presence or absence of preoperative clinically significant portal hypertension (CSPH). RESULTS: Among the 187 CP class A patients, 125 patients (66.8%) were ALBI 1 and 62 patients (33.2%) were ALBI 2. The 5-year overall survival (OS) was 49.2% in the entire cohort and was 57.1% and 33.5% for ALBI 1 and ALBI 2, respectively (P=0.0014). ALBI 2 patients showed a higher rate of post-hepatectomy liver failure (PHLF), 9.7% vs. 2.4% for ALBI 1 (P=0.027). In the multivariate analysis, the ALBI score [hazard ratio (HR) 1.9, P=0.026], stage of fibrosis (HR 2.0, P=0.02) and vascular invasion (HR 3.1, P<0.001) were the independent factors associated with OS. CSPH was identified in 60 (32.1%) patients. Of the patients with CSPH, the 5-year OS was 44.6% and 25.2% for ALBI 1 and ALBI 2, respectively (P=0.031). Of the patients without CSPH, the 5-year OS was 62.5% and 37.6% for ALBI 1 and ALBI 2, respectively (P=0.021). CONCLUSIONS: The ALBI score represents a simple tool to stratify the risk of PHLF and OS in CP class A HCC patients undergoing surgery and to evaluate the prognosis in patients with CSPH. This study justifies the use of the ALBI score in clinical practice to better select patients before surgery.
format Online
Article
Text
id pubmed-8798373
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87983732022-02-02 The albumin-bilirubin score stratifies the outcomes of Child-Pugh class A patients after resection of hepatocellular carcinoma Ruzzenente, Andrea De Angelis, Michela Conci, Simone Campagnaro, Tommaso Isa, Giulia Bagante, Fabio Ciangherotti, Andrea Pedrazzani, Corrado Capelli, Paola Iacono, Calogero Guglielmi, Alfredo Transl Cancer Res Original Article BACKGROUND: The albumin-bilirubin (ALBI) score is a mathematical model including serum albumin and bilirubin, recently proposed as an alternative prognostic tool in patients with hepatocellular carcinoma (HCC). The aims of this study were to provide evidence that the ALBI score can identify different prognostic groups in Child-Pugh (CP) class A patients undergoing liver resection with curative intent and to verify the ability of the ALBI score to predict short-term and long-term outcomes. METHODS: We performed a retrospective analysis on patients classified as class A according to the CP score who underwent liver resection with curative intent for HCC between 2006 and 2016 in the Division of Hepatobiliary Surgery at the University of Verona. Patients were divided according to the ALBI score and the presence or absence of preoperative clinically significant portal hypertension (CSPH). RESULTS: Among the 187 CP class A patients, 125 patients (66.8%) were ALBI 1 and 62 patients (33.2%) were ALBI 2. The 5-year overall survival (OS) was 49.2% in the entire cohort and was 57.1% and 33.5% for ALBI 1 and ALBI 2, respectively (P=0.0014). ALBI 2 patients showed a higher rate of post-hepatectomy liver failure (PHLF), 9.7% vs. 2.4% for ALBI 1 (P=0.027). In the multivariate analysis, the ALBI score [hazard ratio (HR) 1.9, P=0.026], stage of fibrosis (HR 2.0, P=0.02) and vascular invasion (HR 3.1, P<0.001) were the independent factors associated with OS. CSPH was identified in 60 (32.1%) patients. Of the patients with CSPH, the 5-year OS was 44.6% and 25.2% for ALBI 1 and ALBI 2, respectively (P=0.031). Of the patients without CSPH, the 5-year OS was 62.5% and 37.6% for ALBI 1 and ALBI 2, respectively (P=0.021). CONCLUSIONS: The ALBI score represents a simple tool to stratify the risk of PHLF and OS in CP class A HCC patients undergoing surgery and to evaluate the prognosis in patients with CSPH. This study justifies the use of the ALBI score in clinical practice to better select patients before surgery. AME Publishing Company 2019-04 /pmc/articles/PMC8798373/ /pubmed/35117104 http://dx.doi.org/10.21037/tcr.2018.12.10 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Original Article
Ruzzenente, Andrea
De Angelis, Michela
Conci, Simone
Campagnaro, Tommaso
Isa, Giulia
Bagante, Fabio
Ciangherotti, Andrea
Pedrazzani, Corrado
Capelli, Paola
Iacono, Calogero
Guglielmi, Alfredo
The albumin-bilirubin score stratifies the outcomes of Child-Pugh class A patients after resection of hepatocellular carcinoma
title The albumin-bilirubin score stratifies the outcomes of Child-Pugh class A patients after resection of hepatocellular carcinoma
title_full The albumin-bilirubin score stratifies the outcomes of Child-Pugh class A patients after resection of hepatocellular carcinoma
title_fullStr The albumin-bilirubin score stratifies the outcomes of Child-Pugh class A patients after resection of hepatocellular carcinoma
title_full_unstemmed The albumin-bilirubin score stratifies the outcomes of Child-Pugh class A patients after resection of hepatocellular carcinoma
title_short The albumin-bilirubin score stratifies the outcomes of Child-Pugh class A patients after resection of hepatocellular carcinoma
title_sort albumin-bilirubin score stratifies the outcomes of child-pugh class a patients after resection of hepatocellular carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798373/
https://www.ncbi.nlm.nih.gov/pubmed/35117104
http://dx.doi.org/10.21037/tcr.2018.12.10
work_keys_str_mv AT ruzzenenteandrea thealbuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT deangelismichela thealbuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT concisimone thealbuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT campagnarotommaso thealbuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT isagiulia thealbuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT bagantefabio thealbuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT ciangherottiandrea thealbuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT pedrazzanicorrado thealbuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT capellipaola thealbuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT iaconocalogero thealbuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT guglielmialfredo thealbuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT ruzzenenteandrea albuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT deangelismichela albuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT concisimone albuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT campagnarotommaso albuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT isagiulia albuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT bagantefabio albuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT ciangherottiandrea albuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT pedrazzanicorrado albuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT capellipaola albuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT iaconocalogero albuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma
AT guglielmialfredo albuminbilirubinscorestratifiestheoutcomesofchildpughclassapatientsafterresectionofhepatocellularcarcinoma